TAVR (TAVI)
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Chris Malaisrie, a Professor of Surgery in the Division of Cardiac Surgery at Northwestern University and an Attending Cardiac Surgeon at Northwestern Medicine,...
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Aamir Amin, a cardiothoracic surgery resident at Manchester University NHS Foundation Trust, UK, about humanoid robots and artificial...
This session features leading surgeons discussing the tricuspid valve at the Transcatheter Heart Valves Greece (THVGreece) 2026 conference. Moderators Vassilis Voudris, Director of the Cardiology/Interventional Cardiology Division, Onassis Cardiac Surgery...
In this episode of The Atrium, host Dr. Alice Copperwheat speaks with Dr. Filip Casselman, Staff Surgeon and Co-Director of the Cardiovascular Center at OLV Clinic (AZORG), Aalst, Belgium, about...
This video completes a day of excellent presentations by leading surgeons exploring advanced minimally invasive techniques including congenital ventricular septal defect (VSD) surgery, endoscopic transcatheter aortic valve replacement (TAVR) explantation,...
A comparative study between five types of transcatheter heart valves found that although adverse outcome rates are low among all devices, some differences do stand out. The authors found that...
In the past, there has not been an accurate way to calculate mortality risk for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation (TAVI)...
On May 25, 2021, Dr. David Heimansohn successfully performed the first surgical implantation of biopolymer Tria™ heart valve in a patient with mitral valve disease at Ascension St. Vincent Hospital,...
In this article, Thourani et al present the International Society for Minimally Invasive Cardiothoracic Surgery Expert Consensus Statement on transcatheter and surgical aortic valve replacement in low- and intermediate-risk patients:...
In this article, Kilcoyne et al discuss the current status of training cardiothoracic surgery trainees in structural heart disease and propose a new core curriculum for training surgeons in structural...
As TAVR is used in progressively lower-risk cohorts, management of device failure will become increasingly important. This study reports the largest series of patients receiving a surgical reoperation after transcatheter...
Five year results of the PARTNER II trial demonstrated no difference in the risk of stroke or death comparing TAVR to surgical aortic valve replacement among intermediate surgical risk patients....
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy : https://www.nejm.org/doi/full/10.1056/NEJMoa1911425?query=recirc_curatedRelated_article, And...


